Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 0.72 |
| ▸ | JAK1 | P23458 | 11/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.72 |
| ▸ | JAK3 | P52333 | 5/20 | 0.72 |
| ▸ | TYK2 | P29597 | 4/20 | 0.72 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.72 |
| ▸ | PAK4 | O96013 | 2/20 | 0.72 |
| ▸ | ABL1 | P00519 | 2/20 | 0.72 |
| ▸ | RET | P07949 | 2/20 | 0.72 |
| ▸ | LTK | P29376 | 2/20 | 0.72 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.72 |
| ▸ | CLK2 | P49760 | 2/20 | 0.72 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.72 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.72 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.72 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.72 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.72 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.72 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.72 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30846778 | 1.00 | JAK2 (0.72) | JAK2JAK1HDAC6JAK3TYK2 | |
| SCHEMBL19098148 | 1.00 | JAK2 (0.72) | JAK2JAK1HDAC6JAK3TYK2 | |
| SCHEMBL30480818 | 1.00 | JAK2 (0.72) | JAK2JAK1HDAC6JAK3TYK2 | |
| SCHEMBL19098145 | 0.92 | JAK2 (0.72) | JAK2JAK1HDAC6JAK3TYK2 | |
| SCHEMBL20548737 | 0.92 | JAK2 (0.72) | JAK2JAK1HDAC6JAK3TYK2 | |
| SCHEMBL30480817 | 0.92 | JAK2 (0.72) | JAK2JAK1HDAC6JAK3TYK2 | |
| SCHEMBL19098144 | 0.91 | JAK2 (0.70) | JAK2JAK1HDAC6JAK3TYK2 | |
| SCHEMBL25815273 | 0.90 | JAK2 (0.68) | JAK2JAK1HDAC6JAK3TYK2 | |
| SCHEMBL31281026 | 0.89 | JAK2 (0.57) | JAK2JAK1HDAC6JAK3TYK2 | |
| SCHEMBL24505546 | 0.86 | JAK2 (0.74) | JAK2JAK1HDAC6JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215003-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB | GRANULES INDIA LIMITED (IN) | 2025-07-03 | — | — | US | disclosed |
| WO-2024042448-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB | GRANULES INDIA LIMITED (IN) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024042448-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB | GRANULES INDIA LIMITED (IN) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023125373-A1 | METHOD FOR PREPARING RUXOLITINIB AND INTERMEDIATE THEREOF | 江苏威凯尔医药科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20210387991-A1 | NOVEL DEUTERATED JAK INHIBITOR AND USES THEREOF | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2021-12-16 | — | — | US | disclosed |
| CN-111763209-B | Synthesis process of luccotinib | 正大天晴药业集团股份有限公司 | 2021-12-03 | — | — | CN | disclosed |
| WO-2021236139-A1 | NOVEL DEUTERATED JAK INHIBITOR AND USES THEREOF | CONCERT PHARMACEUTICALS, INC. (US) | 2021-11-25 | — | — | WO | disclosed |
| EP-3398952-B1 | SYNTHESIS PROCESS OF RUXOLITINIB | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-07-14 | — | — | EP | disclosed |
| EP-3398952-B1 | SYNTHESIS PROCESS OF RUXOLITINIB | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-07-14 | — | — | EP | disclosed |
| CN-111763209-A | Synthesis process of luccotinib | 正大天晴药业集团股份有限公司 | 2020-10-13 | — | — | CN | disclosed |
| CN-108699063-B | Synthesis process of luccotinib | 正大天晴药业集团股份有限公司 | 2020-06-26 | — | — | CN | disclosed |
| US-10562904-B2 | Synthesis process of ruxolitinib | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-02-18 | — | — | US | disclosed |
| US-10562904-B2 | Synthesis process of ruxolitinib | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-02-18 | — | — | US | disclosed |
| US-20190023712-A1 | SYNTHESIS PROCESS OF RUXOLITINIB | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-01-24 | — | — | US | disclosed |
| US-20190023712-A1 | SYNTHESIS PROCESS OF RUXOLITINIB | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-01-24 | — | — | US | disclosed |
| EP-3398952-A1 | SYNTHESIS PROCESS OF RUXOLITINIB | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2018-11-07 | — | — | EP | disclosed |
| CN-108699063-A | Synthesis process of luccotinib | 正大天晴药业集团股份有限公司 | 2018-10-23 | — | — | CN | disclosed |
| WO-2017114461-A1 | SYNTHESIS PROCESS OF RUXOLITINIB | 正大天晴药业集团股份有限公司 | 2017-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562904-B2 | Synthesis process of ruxolitinib | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885HDAC6 3723/4885 |
| US-20210387991-A1 | NOVEL DEUTERATED JAK INHIBITOR AND USES THEREOF | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885HDAC6 343/4885 |
| US-20250215003-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885HDAC6 2416/4885 |
| US-20190023712-A1 | SYNTHESIS PROCESS OF RUXOLITINIB | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885HDAC6 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.